Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q3 FY2025 Earnings Presentation
24 slides from Lincoln Pharmaceuticals's earnings presentation, 2025
Slide 1: Q3 FY2025 Earnings Presentation
Q3 FY2025 PHARMACEUTICALS LTD Earnings Presentation HEALTHCARE FORALL GROWING IS COMMITEMENT. www.lincolnpharma.com
Slide 2: Disclaimer
Disclaimer The information, statements and analysis made in this presentation describing Company’s objectives, projections and estimates are forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which cou
Slide 3: Corporate Overview
Corporate Overview Background Product Portfolio Manufacturing Exports Established in the year 1979, 1700 registered products Manufacturing facility at Khatraj, Exports contribute 62.4% in FY24; Lincoln Pharma has developed and another 700 in pipeline. Ahmedabad and Mehsana, Gujarat. Domestic Sales c
Slide 4: 9 Months FY25 Business Performance & Future Road Map
9 Months FY25 Business Performance & Future Road Map • Company has continued its growth journey while maintaining a net debt-free status. New product launches in domestic and export markets have strengthened company’s market presence. • For Q3 FY25 company reported a Net profit of Rs. 20.77 crore, E
Slide 5: 9 Months FY25 Consolidated Results
9 Months FY25 Consolidated Results TOTAL INCOME EBITDA NET PROFIT 465.46 484.40 108.93 104.13 74.71 70.77 9 Months FY24 9 Months FY25 9 Months FY24 9 Months FY25 9 Months FY24 9 Months FY25 Fig (RsCr) Q3 FY2025 Earning Presentation
Slide 6: Q3 FY25 Performance – Focused Therapeutic Areas
Q3 FY 25 Performance – Focused Therapeutic Areas Therapy Area Q3 FY25 Q3 FY24 General Anti Infectives 30.3% 28.1% Respiratory Systems 8.0% 7.3% 27.8% 28.1% Alimentary Tract andMetabolism 5.8% 4.9% 29.2% 30.3% Genito Urinary System and Sex Hormones 1.0% 0.9% Musculo-Skeletal System 11.9% 17.0% Q3 FY2
Slide 7: Q3 and Nine Months FY25 Performance Overview
Q3 and Nine Months FY25 Performance Overview CONSOLIDATED FINANCIAL PERFORMANCE (Rs in Cr.) PARTICULARS Q3 Y-o-Y 9 Months Y-o-Y FY2025 FY2024 Growth (%) FY2025 FY2024 Growth (%) Total Income 155.52 157.46 -1.23% 484.40 465.46 4.07% EBITDA 32.63 40.68 -19.79% 104.13 108.93 -4.41% Profit BeforeTax 28.
Slide 8: About Lincoln Pharmaceuticals Ltd
AboutLincoln Pharmaceuticals Ltd Providing Affordable And Innovative Medicines For Healthier Lives. Vision To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging strategic alliances both domestically and internationally. Mission Focused on delivering o
Slide 9: Key Milestones
Key Milestones 1979 1996-97 2010-11 2016-17 Listed on NSE. Domestic marketexpansion; Install 2.1 MW windmill Launched nextgeneration Received WHO-GMPfor Covered 80% of India market. in addition to 6000 progesterone therapy - plant/production unit. KVA in 2009. ProlinSpray. Lincoln wasincorporated an
Slide 10: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap CAPEX The company has completed the expansion of its Cephalosporin plant in Mehsana, Gujarat, and has commenced commercial production, with sales initiated in domestic markets. Plans are underway to register the product for export to multiple countries. C
Slide 11: Five Years Financial Overview
Lincoln Pharmaceuticals Ltd – Five Years Financial Overview Year Total Income EBITDA Net Profit EPS Share Price FY 24 614.97 134.33 93.37 46.58 585.40 FY 19 371.83 72.87 48.77 24.36 212.55 5 Yrs CAGR 10.6% 13.0% 13.9% 13.9% 22.5% Book Yalue (Per Share) Market Cap (Rs Cr) Net Debt (Rs Cr) 296 1173 25
Slide 12: Business Revenue Mix
Business Revenue Mix FY13 FY17 FY24 25.5% 32.6% 37.6% 62.4% 67.4% 74.5% DOMESTIC SALES EXPORT Q3 FY2025 Earning Presentation
Slide 13: Global Footprints
Global Footprints Presence over 60+ countries in Europe, Canada, Latin & North America, Africa, Asia Pacific, South East Asia, and 26 states across India. Srinagar Jammu Chandigarh Uttrakhand North America: Ambala Ghaziabad Europe: Delhi Canada. France. Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad
Slide 14: Research & Development
Research & Development NDDS Formulations Introduced First Time In India by Lincoln Anti-Fungal VaginaSpray. Diclofenac RectalSpray. Sildenafil Oral Spray. Ondansetron Hydrochloride Oral Spray (DOMI-UP). Paracetamol 1000mg Programmed ReleaseTablet (PA-12). Micronized Progesterone Vaginal Spray (PROLI
Slide 15: Innovations – Lincoln Pharma
Innovations – LINCOLN PHARMA Q3 FY2025 Earning Presentation
Slide 16: New Launches – Domestic Market
New Launches – Domestic Market Q3 FY2025 Earning Presentation
Slide 17: New Launches – International Markets
New Launches – International Markets Q3 FY2025 Earning Presentation
Slide 18: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough &Cold/ Dermatologist Gyneacological Sterile Ophthalmic Gastro Intestinal Anti Allergic/ Preparation Products Eye Drops/ Range Anti-asthmatics Ointment Vitamins/ Anti-bacterial/ Anti-viral/ Analgesic/ Anti-Malarial M inerals/ Otology Anti-fungal Anti-pyreti
Slide 19: Best In Class Facilities – Khatraj, Gujarat
Best In Class Facilities – Khatraj, Gujarat Certification EU-GMP, TGA, WHO-GMP Certified; ISO 9001:2015; ISO-14001:2015 and ISO-45001:2018 Certified. R&D Center Approved by Government of India;Team of 30 plus scientists for R&D. Green Energy Windmill and 1MW Solar Roof installed. Producing 65% of co
Slide 20: Best in Class Facilities – Mehsana, Gujarat
Best in Class Facilities – Mehsana, Gujarat WHO-GMP Certified; BOMRA Certified; ISO 9001:2015; ISO-14001:2015 and Certification ISO-45001:2018 Certified. Approved Team of 10 plus scientists for R&D. R&D Center Dosage Forms Produced at Unit 3 OSD and Dry Powder Injection Description Size Annual Capac
Slide 21: Financial Highlights
Financial Highlights TOTAL INCOME NET PROFIT 93.4 615.0 532.8 72.9 482.1 69.4 428.7 62.3 396.3 51.5 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 EBITDA NET WORTH Fig (RsCr) 134.3 592.8 111.7 502.5 105.5 432.9 92.8 76.5 366.4 304.1 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 Q3 FY2025 Earn
Slide 22: Profitability Ratios
Profitability Ratios EBITDA MARGIN PAT MARGIN 21.6% 21.9% 21.8% 14.5% 15.2% 21.0% 14.4% 13.7% 19.3% 13.0% FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 ROCE RONW 22.0% 22.6% 21.9% 19.9% 20.4% 16.9% 17.0% 16.0% 15.7% 14.5% FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 Q3 FY2025 Earning Presen
Slide 23: Share Holding Information
Share Holding Information Particulars December 2024 March 2024 Investor Category No of Shareholders No of Shares Held Holding (%) No of Shareholders No of Shares Held Holding (%) Promoter Group 25 99,69,930 49.78% 25 99,21,430 49.53% Public Holding 31,823 1,00,59,798 50.22% 31,350 1,01,08,298 50.47%
Slide 24: Location
Location Corporate Office Lincoln House B/h Satyam Complex, Science City Road, Sola Ahmedabad - 380060,Gujarat, India. Phone: +91 - 79 - 4107 8000 l Fax: +91- 79 - 4107 8062 Email: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit Shah Gopal Modi CFO, Lincoln Pharm
Lincoln Pharmaceuticals — Q3 FY2025 Earnings Presentation on 6ix